Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
ESMO Open|May 20, 2021
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?N Y L Ngoi, D S P TanBritish Journal of Cancer|April 6, 2013
New perspectives on molecular targeted therapy in ovarian clear cell carcinomaD S P Tan, R E Miller, S B KayeJournal of Clinical Pathology|August 7, 2008
Hereditary breast cancer: from molecular pathology to tailored therapiesD S P Tan, C Marchiò, J S Reis-FilhoThe Journal of Pathology|September 13, 2008
ESR1 amplification in endometrial carcinomas: hope or hyperbole?D S P Tan, M B K Lambros, C Marchiò, et al.The British Journal of Surgery|September 4, 2020
Maintaining breast cancer care in the face of COVID-19C W Q Ng, M Tseng, J S J Lim, et al.Journal of Clinical Pathology|June 30, 2009
Genomic profile of a secretory breast cancer with an ETV6-NTRK3 duplicationM B K Lambros, D S P Tan, R L Jones, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2021
The systemic treatment of recurrent ovarian cancer revisitedT Baert, A Ferrero, J Sehouli, et al.Gynecologic Oncology Reports|June 13, 2018
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancerN Y L Ngoi, V Heong, X W Lee, et al.ESMO Open|May 17, 2025
First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab, in patients with advanced malignanciesF Janku, D S P Tan, J Martin-Liberal, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroupsN Z H Wong, D W T Yap, R J M Ong, et al.Pageof 2